Search bioRxiv⌕ Search

Biology subjects

Hoelzli, E.

Publications and source records attributed to Hoelzli, E..

2 recordsLinked to original sources

ML-driven design of 3' UTRs for mRNA stability

Using mRNA as a therapeutic has received enormous attention in the last few years, but instability of the molecule remains a hurdle to achieving long-lasting therapeutic levels of protein expression. In this study, we describe our approach for designing stable mRNA molecules by combining machine learning-driven sequence design with high-throughput experimental assays. We developed a high-throughput massively parallel reporter assay (MPRA) that, in a single experiment, measures the half-life of tens of thousands of unique mRNA sequences containing designed 3 UTRs. Over multiple design-build-test iterations, we have accumulated mRNA stability measurements for 180,000 unique genomic and synthetic 3 UTRs, representing the largest such dataset of sequences. We trained highly-accurate machine learning models to map from 3 UTR sequence to mRNA stability, and used them to guide the design of synthetic 3 UTRs that increase mRNA stability in cell lines. Finally, we validated the function of several ML-designed 3 UTRs in mouse models, resulting in up to 2-fold more protein production over time and 30-100-fold higher protein output at later time points compared to a commonly used benchmark. These results highlight the potential of ML-driven sequence design for mRNA therapeutics.

synthetic biology↗

Cell-type specific gene expression profiling in heterogeneous in vitro cultures using epitope-tagged RPL22

Genetic and genomic studies of brain disease increasingly demonstrate disease-associated interactions between the cell types of the brain. Increasingly complex and more physiologically relevant human induced pluripotent stem cell (hiPSC)-based models better explore the molecular mechanisms underlying disease, but also challenge our ability to resolve cell-type specific perturbations. Here we report an extension of the RiboTag system, first developed to achieve cell-type restricted expression of epitope-tagged ribosomal protein (RPL22) in mouse tissue, to a variety of in vitro applications, including immortalized cell lines, primary mouse astrocytes, and hiPSC-derived neurons. RiboTag expression enables efficient depletion of off-target RNA in mixed species primary co-cultures and in hiPSC-derived neural progenitor cells, motor neurons, and GABAergic neurons. Nonetheless, depletion efficiency varies across independent experimental replicates. The challenges and potential of implementing RiboTags in complex in vitro cultures are discussed.

molecular biology↗